|
UBE2K expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.005000E-04 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.079900E-03 |
| Normal-vs-Stage2 |
6.349800E-02 |
| Normal-vs-Stage3 |
7.369300E-04 |
| Normal-vs-Stage4 |
3.83440000000235E-05 |
| Stage1-vs-Stage2 |
6.290000E-01 |
| Stage1-vs-Stage3 |
3.614000E-01 |
| Stage1-vs-Stage4 |
6.262400E-02 |
| Stage2-vs-Stage3 |
3.192200E-01 |
| Stage2-vs-Stage4 |
8.286500E-02 |
| Stage3-vs-Stage4 |
2.945600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.413330E-04 |
| Normal-vs-AfricanAmerican |
3.114800E-01 |
| Normal-vs-Asian |
9.017900E-04 |
| Caucasian-vs-AfricanAmerican |
1.251760E-01 |
| Caucasian-vs-Asian |
8.489800E-01 |
| AfricanAmerican-vs-Asian |
1.216830E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.243300E-04 |
| Normal-vs-Female |
1.700570E-03 |
| Male-vs-Female |
3.702200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.863200E-03 |
| Normal-vs-Age(41-60Yrs) |
7.159200E-04 |
| Normal-vs-Age(61-80Yrs) |
3.969500E-04 |
| Normal-vs-Age(81-100Yrs) |
1.715040E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.504800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.830800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.731600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.840600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.909600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.957800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.446000E-02 |
| Classical-VS-Follicular |
5.832000E-01 |
| Classical-VS-Other |
7.306500E-02 |
| Classical-VS-Normal |
4.858900E-03 |
| Tall-VS-Follicular |
1.612760E-01 |
| Tall-VS-Other |
3.395400E-01 |
| Tall-VS-Normal |
2.432400E-04 |
| Follicular-VS-Other |
1.901580E-01 |
| Follicular-VS-Normal |
1.078110E-02 |
| Other-VS-Normal |
3.796200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.024800E-04 |
| Normal-vs-N1 |
1.52259999999238E-05 |
| N0-vs-N1 |
4.570000E-02 |
|
|
